Argobio is a start-up studio dedicated to novel therapeutics aiming to nurture and launch breakthrough Biotech companies. Argobio sources innovative early-stage projects from renowned European academic research institutions with the objective of incubating these projects before company creation. The focus is on rare diseases, neurological disorders, oncology, and immunology. The studio also look to develop promising platform technologies for therapeutic products.
Argobio was initiated by Kurma Partners, Bpifrance, Angelini Pharma, Evotec and Institut Pasteur who have committed 50M € to Argobio.
Company Details
- Employees
- 22
- Founded
- -
- Address
- 8 Rue François Villon, Paris,75015,france
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.argobiostudio.com/
- HQ
- Paris
Argobio Studio Questions
Argobio Studio's website is https://www.argobiostudio.com/
Argobio Studio's LinkedIn profile is https://fr.linkedin.com/company/argobio
Argobio Studio has
22 employees.
View email and phone details for 22
employees at Argobio Studio.
Argobio Studio's industry is
Biotechnology Research
Argobio Studio's top competitors are
Crucible Therapeutics,
Rosetta Omics,
Kurma Partners,
Elkedonia,
Enodia Therapeutics,
Allero Therapeutics Bv,
Thesian Bio,
Temper Bio,
Laigo Bio,
Inverna Therapeutics.
Argobio Studio's categories are Biotechnology Research
Argobio Studio's founding year is 2021
